J&J's Centocor Buy Eyes Potential $4 Bil. ReoPro Market To Spur Stent Sales
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's $4.9 bil. stock acquisition of biotechnology firm Centocor is motivated in part by the potential for Centocor's antiplatelet monoclonal antibody-based drug ReoPro (abciximab) to boost sales of coronary stents by J&J's Cordis unit.